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Abstract
Background: Others and we have previously described the potent in vivo and in vitro activity of
the broad-spectrum antiviral agent PAP (Pokeweed antiviral protein) against a wide range of
viruses. The purpose of the present study was to further elucidate the anti-viral spectrum of PAP
by examining its effects on the survival of mice challenged with lymphocytic choriomeningitis virus
(LCMV).
Methods: We examined the therapeutic effect of PAP in CBA mice inoculated with intracerebral
injections of the WE54 strain of LCMV at a 1000 PFU dose level that is lethal to 100% of mice within
7–9 days. Mice were treated either with vehicle or PAP administered intraperitoneally 24 hours
prior to, 1 hour prior to and 24 hours, 48 hours 72 hours and 96 hours after virus inoculation.
Results: PAP exhibits significant in vivo anti- LCMV activity in mice challenged intracerebrally with
an otherwise invariably fatal dose of LCMV. At non-toxic dose levels, PAP significantly prolonged
survival in the absence of the majority of disease-associated symptoms. The median survival time
of PAP-treated mice was >21 days as opposed to 7 days median survival for the control (p =
0.0069).
Conclusion: Our results presented herein provide unprecedented experimental evidence that
PAP exhibits antiviral activity in the CNS of LCMV-infected mice.
Background
The broad-spectrum anti-viral agent PAP (Pokeweed anti-
viral protein) [1] is a well-characterized 29-kDa plant-
derived ribosome-inactivating protein (RIP) isolated from
Phytolacca americana [2]. The anti-viral activity of PAP
has been described against a wide range of viruses, includ-
ing HIV-1, herpes simplex virus, cytomegalovirus, influ-
enza virus and polio virus [2] (For the most recent review,
please see: [3]). The activity of PAP is attributed to its abil-
ity to inhibit protein synthesis by catalytically cleaving a
specific adenine base from the highly conserved alpha-
sarcin/ricin loop (SRL) of the large ribosomal RNA [4,5]
as well as from viral RNA[3]. The potent anti-HIV activity
of PAP at nanomolar ranges taken together with the rela-
tive ease of large scale purification has led to the clinical
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tifunctional efficacy of this potent agent [1,2,4-42].
The purpose of the present study was to further elucidate
the anti-viral spectrum of PAP by examining its effects on
survival of mice challenged with intracerebral inocula-
tions of lymphocytic choriomeningitis virus (LCMV).
LCMV is a rodent-borne arena virus that can result in per-
sistent neuronal infection on mice [43,44]. Alpha-Dystro-
glycan (alpha-DG) was recently identified as a receptor for
LCMV as well as for several other arena viruses including
Lassa fever virus [45]. The binding affinity of LCMV to
alpha-DG determines viral tropism and the outcome of
infection in mice [46]. LCMV has also been associated
with both postnatal and intrauterine human disease.
Infection in man is acquired after inhalation, ingestion or
direct contact with virus found in the urine, feces and
saliva of infected mice, hamsters and guinea pigs. Con-
genital LCMV infection is a significant, often unrecog-
nized cause of chorioretinitis, hydrocephalus,
microcephaly or macrocelphaly as well as mental retarda-
tion. Acquired LCMV infection, asymptomatic in approx-
imately one third of individuals, is productive of central
nervous system manifestations in one half of the remain-
ing cases. Aseptic meningitis or meningoenceophalitis are
the predominant syndromes, although transverse myeli-
tis, a Guillain-Barre-type syndrome, as well as transient
and permanent acquired hydrocephalus have also been
reported [47].
In the present study, we describe the significant efficacy of
the highly stable, potent and broad-spectrum anti-viral
agent PAP in a murine model of LCMV. Our results pre-
sented herein provide unprecedented experimental evi-




PAP was purified from spring leaves of the pokeweed
plant, P. americanca, in four steps [22,38]. Briefly, spring
leaves were homogenized in a neutral pH buffer and cen-
trifuged to sediment the remaining cellular fragments. The
supernatant was fractionated between 60–90% saturation
of ammonium sulfate and the precipitate dialyzed against
a low-ionic strength pH 7.5 buffer. The solution was
passed through a DEAE cellulose column and the PAP-
containing flow-through fraction was then applied to a
cation exchange resin S-Sepharose column. The adsorbed
PAP was eluted in a linear KCl gradient. The protein peak
which eluted at 0.12 KCl was taken as PAP. This fraction
was dialyzed extensively against water and lyophilized for
storage at -20°C. The procedure resulted in homogeneous
PAP, with a purity of >99% as measured by both SDS -
12% PAGE and analytical cation- exchange high-perform-
ance liquid chromatography. Purified PAP induced con-
centration-dependent inhibition of HIV-1 replication in
normal human peripheral blood mononuclear cells
infected with the HIV-1 strain HTLVIIIB with an IC50 p24 of
14 ± 2 nM.
Animal infection
Animal infection was performed in an appropriate Ani-
mal BioSafety Level-3 Laboratory (ABL-3) at BRIEM
(Research Institute for Epidemiology and Microbiology,
MINSK, Belarus) with the technician wearing appropriate
facility clothing. The culture was thawed in a water bath at
37°C and then diluted in normal saline to achieve the
required concentration. In this study, all mice were chal-
lenged with 1000 PFU which is 100-times higher than the
LD50 dose. Each group of animals was placed in a separate
cage.
LCMV model
Three week old CBA mice were intracerebrally infected
with 1000 PFU of WE54 strain of LCMV that resulted in
lethality of 100% of control (non-treated) animals in 6–8
days after infection. Control animals were given physio-
logic salt solution as a placebo instead of the compound.
In general, for non-treated animals, clinical signs of the
disease manifested on the 5th and 7th days by presenting:
weight loss, immobility, disheveled hair, convulsions,
severe decubitus paralysis and death. All subjective meas-
urement of decreased mobility and scruffy fur were done
in a blinded fashion as not to influence the results. The
protective properties of the experimental anti-viral drugs
were assessed by using the following treatment-preventa-
tive regimen: Mice were treated either with vehicle (n =
20) or PAP (n = 10) (0.25 mg/kg) administered intraperi-
toneally 24 hours prior to, 1 hour prior to, and 24 hours,
48 hours, 72 hours, and 96 hours after virus inoculation.
Mice were then observed for 21-days post infection. The
protective effect of the experimental anti-viral drugs was
evaluated according to the rise of the survival rate and pro-
longation of mean life of the experimental animals as
compared with the control animals.
Statistical analysis
Statistical significance was determined using the Kaplan
Meier Log-Rank test.
Results
In order to evaluate the anti-LCMV activity of PAP, mice
were inoculated with intracerebral injections of LCMV at
a dose level that is lethal to 100% of mice within 6–8 days.
Mice were treated either with vehicle or PAP as described
in the methods section. Of the 20 control mice, 3 died on
day 1 immediately after intracerebral injection due to acci-
dental brain injury and are excluded from the data analy-
sis. All 17 of the remaining control mice developedPage 2 of 7
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including weight loss, disheveled hair, decreased mobility
and paralysis (Table 1). All control mice developed sei-
zures between day 5 and day7 and died between day 6 and
day 8 with a median survival of 7 days (Table 1, Figure 1).
Of the 10 mice treated with the broad-spectrum antiviral
agent pokeweed antiviral protein (PAP), 2 died on day 1
immediately after intracerebral injection due to accidental
brain injury and are invaluable. Five of the remaining 8
mice (62.5%) treated with PAP remained alive > 21 days
post-LCMV inoculation (median survival >21 days, p =
0.0069) (Table 1, Figure 1). These mice exhibited no
LCMV infection-related weight loss or convulsions and
showed no signs of scruffy fur. A significant improvement
in mobility was also noted. Thus, PAP exhibited signifi-
cant in vivo anti-LCMV activity in mice challenged intrac-
erebrally with an otherwise invariably fatal dose of LCMV.
Discussion
In the present study, we describe the significant efficacy of
the highly stable, potent and broad-spectrum anti-viral
agent PAP in a murine model of LCMV. Our results pre-
sented herein provide unprecedented experimental evi-
dence that PAP exhibits antiviral activity in the CNS of
LCMV-infected mice. Future studies will examine the ther-
apeutic activity of PAP against LCMV in post-challenge
settings. As PAP is well described as an HIV agent, this
observation is also relevant as HIV-1 infects the central
nervous system (CNS) and it has been feared that the CNS
Table 1: Anti-LCMV activity of PAP in CBA mice
Disease Unset
Days after inoculation with LCM Virus
Survival (days) Weight loss 
(grams)
Decreased mobility Convulsions Hair disheveled
Vehicle
Mouse #1* <<1 NA 0 NA NA
Mouse #2* <<1 NA 0 NA NA
Mouse #3* <<1 NA 0 NA NA
Mouse #4 6 1.5 4.5 5.5 4.5
Mouse #5 6 2 4.5 5.5 4.5
Mouse #6 7 2 5 6 5
Mouse #7 7 1.5 5 6 5
Mouse #8 7 2.5 5 6 5
Mouse #9 7 4.5 5 6 5
Mouse #10 7 4.5 5 6 5
Mouse #11 7 4.5 5 6 5
Mouse #12 8 2 6 7 6
Mouse #13 8 2.5 6 7 6
Mouse #14 8 1 6 7 6
Mouse #15 8 1.5 6 7 6
Mouse #16 8 2 6 7 6
Mouse #17 8 2 6 7 6
Mouse #18 7 1.5 5 6 5
Mouse #19 8 2 6 7 6
Mouse #20 8 1.5 6 7 6
PAP 0.25 mg/kg
Mouse #1 <<1 NA NA NA NA
Mouse #2 <<1 NA NA NA NA
Mouse #3 6 1 4.5 5.5 5
Mouse #4 7 1.5 5 6 5
Mouse #5 8 1.5 6 7 5.5
Mouse #6 21 0 10 NO NO
Mouse #7 21 0 10 NO NO
Mouse #8 21 0 10 NO NO
Mouse #9 21 0 10 NO NO
Mouse #10 21 0 10 NO NO
*Mouse died after intracerebral injection; NA = not applicable, NO = not observedPage 3 of 7
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tinue to replicate despite otherwise effective antiretroviral
treatment [48,49]. Antiretroviral therapy of HIV-infected
children is associated with a decline in CSF HIV RNA and
an improvement in neurological status. The development
of genotypic mutations was different in CSF and plasma,
suggesting discordant viral evolution. These results sug-
gest that antiretroviral treatment in children should
include agents with activity in the CNS [50]. While these
results suggest that PAP crosses the blood brain barrier
Protective Activity of PAP in CBA Mice Challenged with LCM VirusFigure 1
Protective Activity of PAP in CBA Mice Challenged with LCM Virus. CBA mice were inoculated with intracerebral 
injections of the WE54 strain of LCMV at a 1000 PFU dose level that is lethal to 100% of mice within 7–9 days. Mice were 
treated either with vehicle or PAP administered intraperitoneally 24 hours prior to, 1 hour prior to and 24 hours, 48 hours 72 
hours and 96 hours after virus inoculation. Mice were then observed twice daily for 21 days for morbidity and mortality. (Top) 
Shown are representative survival curves detailing the cumulative proportions (%) of mice surviving after virus inoculation. See 
Table 1 for more detailed information of the treatment outcome. (Bottom) Shown is Kaplan-Meir life-table analysis and statisti-
cal comparison using the log-rank test.Page 4 of 7
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affecting CNS, they need to be interpreted with due cau-
tion for HIV infections involving the CNS since LCMV
affects leptomeninges while HIV affects neurons. In future
studies, we must also consider the possibility that PAP
penetrates the blood brain barrier only when the latter is
impaired by the intracerebral administration of the virus.
If this is the case, PAP may not be useful in pre-challenge
prophylaxis against LCMV-mediated CNS infection.
While these results support the notion that the antiviral
activity spectrum of PAP covers LCMV as well, an immu-
nomodulatory effect of PAP may also contribute to the
observed prophylactic efficacy of PAP against LCMV.
Cases of LCMV infections have been reported in Europe,
the Americas, Australia, and Japan. According to the
Center for Disease Control, currently there is no specific
drug therapy for LCMV. Although the anti-viral agent rib-
avirin is effective against LCMV in vitro, there is no estab-
lished evidence to support its use for treatment of LCMV
in humans [51].
The anti-viral activity of PAP has been described against
numerous pathogenic viruses, which included poliovirus,
HIV-1, herpes simplex virus, cytomegalovirus, influenza
virus and now, the negative-strand RNA virus Lym-
phocytic choriomeningitis virus. The ability of PAP to
inhibit viral protein synthesis and depurinate viral RNA
and DNA [15,16] as well as capped rRNA and mRNAs [52]
and its ability to inhibit ribosomal frame shifting and
retransposition, make it and ideal candidate for anti-viral
strategies.
Conclusion
Treatment of CBA mice with the broad-spectrum anti-viral
agent, PAP significantly improved the probability of sur-
vival following the LCMV challenge and decreased overall
LCMV-related symptoms. The ability of PAP to exhibit
anti-viral activity within the central nervous system is also
encouraging within the framework of potential HIV-treat-
ment. We have recently described the rational design and
engineering of several recombinant PAP mutants with
superior anti-HIV activity [11,17]. In our future studies,
we plan to describe the potential anti-LCMV activity of
these PAP mutants as well as optimizing the prophylactic
and post-exposure treatment regimens. In addition, it will
be important to determine if PAP or PAP mutants have
activity against other viruses associated with lethal viral
hemorrhagic fevers and/or encephalomyelitis, such as the
Ebola viruses of the Filoviridae family [53-56].
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